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Low level light therapy in the management of paediatric oral and 
oropharyngeal mucositis 
  
Abstract (100 words) 
Oral and oropharyngeal mucositis is a common, debilitating condition experienced by 
patients undergoing oncology treatment. There are many different management strategies, 
with low level light therapy (LLLT) an emerging field. 
Ongoing research on the topic of LLLT for mucositis has resulted in LLLT being included in 
national clinical guidelines. The number of centres currently using LLLT for paediatric 
patients with oropharyngeal mucositis is growing, with Glasgow having successfully used 
this treatment method for a number of years. 
Across medicine and dentistry, LLLT is coming to the fore and is a treatment modality we 
should all be aware of. 
 
 
CPD/Clinical Relevance 
New technologies and treatment modalities are areas that practitioners should stay up to 
date with. Low level light therapy continues to be a growing research field. 
 
 
Objective: The reader should understand the significance of oral and oropharyngeal 
mucositis for the paediatric oncology patient and the relevance of low level light therapy 
towards its management. 
 
 
 
Oral and Oropharyngeal mucositis 
Oral and oropharyngeal mucositis occurs in 52-80% of children undergoing treatment for 
cancer.1   Mucositis is a debilitating condition which can be so severe it can delay or stop 
oncology treatment. The mucositis disease process is initiated by chemotherapy or 
radiotherapy at 0-2 days, followed by cell damage at 2-10 days. Frank ulceration and 
mucosal damage occurs at 10-15 days and finally healing after 2-3 weeks. The clinical 
presentation is a combination of erythema and ulceration; and as healing begins, mucosal 
sloughing affects the intra-oral tissues and oesophageal tract. Maintaining adequate oral 
hygiene is difficult due to oral discomfort which may further exacerbate the condition and 
increase a patient’s vulnerability to developing infection. The consequences for paediatric 
patients are significant; eating, drinking, speaking and engaging with those around them 
can be significantly restricted which presents concerns regarding recovery and physical 
and mental wellbeing. Psychological distress has been described by parents of children 
suffering from mucositis at a time when stress and anxiety of the parent and child is 
already amplified by many other factors.2 
 
 
 
 
 
 
 
Figure 1
 
 
 
 
 
Mucositis can be graded using the ‘World Health Organisation (WHO) Grading,’ which 
comprises gradings zero to four 3, as can be seen in the table below. Both the clinical 
presentation and functional outcomes form the basis for this grading system: 
 
 
WHO Grading Description 
0 Healthy mucosa 
1 Pain with no ulceration 
2 Ulcers and erythema but the patient is still able to 
swallow a solid diet 
3 The patient cannot swallow a solid diet; 
4 Mucositis is so severe that alimentation is not 
possible 
 
 
 
Management of mucositis 
General management of mucositis often involves a mixture of preventive and symptomatic 
control measures such as; oral hygiene instruction, soft diet, cryotherapy, protective gels, 
analgesics ranging from paracetamol and non-steroidal analgesia to narcotic analgesia, 
topical anaesthetics,  benzydamine hydrochloride sprays or mouthwashes and 
chlorhexidine and calcium phosphate mouthrinses. Many of these, for example 
mouthwashes, require a certain degree of cooperation and maturity which not all 
paediatric patients will have. Mucositis is such a common and significant problem in 
oncology that many different guidelines have been developed to assist practitioners. 
Guidelines published in 2012 by the The Royal College of Surgeons of England and The 
WHO Mucositis Grading 
 
British Society for Disability and Oral Health 4  recommend benzydamine hydrochloride 
mouthwash, cryotherapy, intravenous keratinocyte growth factor-1 (palifermin), 
anaesthetic mouthwash and analgesia as options to consider in the management of 
mucositis.  More recent guidelines published in 2014 by the Multinational Association of 
Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) similarly 
advises most of  the above mentioned interventions along with other weaker evidence for 
options such as doxepin mouthwash and zinc supplements.5   A guideline by Sung et al in 
2015 included a weak recommendation for cryotherapy to prevent mucositis.6  Both 
MASCC/ISCOO 5 and Sung et al 6 also recommend LLLT as an option for managing 
mucositis. It is anticipated with new evidence emerging that all future guideline revisions 
will also soon advocate Low Level Light Therapy. 
 
 
Low Level Light therapy 
 
Low level light therapy (LLLT) is emerging as an effective treatment modality in both 
medicine and dentistry for a range of conditions. LLLT involves the use of a low power 
laser emitting less than 500mW on the red or near infra-red spectrum with light 
wavelengths of 600nm-1000nm. On applying the light to areas of the body, cells are 
stimulated thereby reducing inflammation, increasing cell metabolism and inducing 
endorphins.  A Dental Update article by Milward et al. in 2014 7 describes in further detail 
the mechanism of action including wound repair, analgesia and anti-inflammatory effects.  
The combination of cellular effects has led to this therapy becoming a widely studied topic 
and gathering increasing attention from the medical and dental professions. Despite the 
growing body of evidence, a recent systematic review of by Hadis et al 8 found 
inadequacies in the reporting of LLLT studies,  with incomplete information available on 
wavelength, light source type, power, pulse frequency, beam area, irradiance, exposure 
time, radiant energy and fluence 
 As mentioned, low level light therapy can be considered for a number of different 
conditions. Research in medical patients has resulted in a Cochrane review on the use of 
LLLT in rheumatoid arthritis, providing evidence that it reduces pain and stiffness.9  
Systematic reviews on its use in treating trigeminal neuralgia 10 and recurrent aphthous 
ulceration 11 are also available in the literature. Ayyildiz et al discusses LLLT for use on 
patients suffering from Temporomandibular Joint Dysfunction with limited mouth 
opening.12   There has also been research involving orthodontic patients concerning the 
potential for LLLT to accelerate tooth movement and also reduce orthodontic related pain 
13,14 . 
 
 
Low Level Light therapy and mucositis 
 
In the literature there have been many studies involving LLLT as a treatment modality for 
oral and oro-pharyngeal mucositis. In a systematic review with meta-analysis by Bjordal et 
al,15 Low Level Light Therapy was shown to reduce pain, severity and duration of 
mucositis. This paper included 11 randomised placebo controlled trials with a total of 415 
patients. The relative risk of developing mucositis was found to be significantly reduced 
after LLLT when compared to placebo (RR = 2.03 p value = 0.02). In patients with 
mucositis, the number of days patients had mucositis was found to be reduced for severity 
gradings 2 or more from 4.38 days to 1.33 days compared with placebo.  
 
A randomised controlled study by Khun et al 16   in 2009, recommended LLLT as a first-line 
option in paediatric patients with chemotherapy-induced oropharyngeal mucositis. The trial 
compared treatment for mucositis with placebo for 5 days compared to LLLT for the same 
duration of time. Twenty-one patients were included in the study with the number of days 
patients had mucositis decreasing from a mean duration of 8.9 days with placebo to a 
mean duration of 5.8 days with LLLT. 
 
The benefits that LLLT can offer to the paediatric patient appear to be significant. As this is 
often a patient group where cooperation may be limited, quick, efficient and effective 
treatment is necessary. In addition paediatric oncology patients in particular are a group 
where the prevention of infection and pain are of paramount importance. 
 
 
Low Level Light therapy use for paediatric patient in Glasgow 
 
Currently in the Royal Hospital for Children  (previously The Royal Hospital for Sick 
Children) in Glasgow, LLLT is used daily in the management of oro-pharyngeal mucositis 
by the Paediatric Dentistry department. It is used often in conjunction with previously 
described measures such as mouth rinses, analgesia and protective gels. The paediatric 
dental team makes regular visits to the oncology ward and has a good relationship with 
the ward staff allowing a team approach to the provision of LLLT. LLLT is delivered using a 
Diobeam 830 laser (830nm) with an output of 150mW (see Figure 2).   Bensadoun at al 
2015 17 recommended that  wavelengths of 633-685nm or 780-830 nm and  power output 
between 10 and 150 mW  are used to treat mucositis.  
 
 
 
 
 Figure 2 
Initially an extra- and intra-oral examination by a qualified dentist determines the areas 
affected by mucositis and a WHO mucositis grading is assigned. An administered dose 
(J/cm2) is then delivered according to the severity of mucositis.3   The paperwork 
completed for each treatment episode used can be seen below in Figure 3.  Although in 
Glasgow the’ laser’ is primarily used for symptomatic mucositis, one joule setting per 
centimetre squared is available for use on healthy mucosa, which would allow for the laser 
to be given as prophylactic treatment. The Diobeam laser is classed as a 3B laser which 
means it carries an ocular hazard. Local laser safety precautions are employed, such as 
using safety glasses to protect the patient, parent’s and user's eyes. The laser is used in 
an approved room which has blinds on the windows, a locked door and safety signs 
displayed outside. LLLT is not visible but has a red guide light to help the user to visualise 
the target area and an auditory guide for when the laser is active. Treatment is painless. 
Similar to radiographic regulations, there are also local laser rules which have to be 
followed and training must be completed prior to any clinician delivering treatment. 
Figure 3 
  
 A pilot study completed in 2012 involving 15 patients demonstrated a statistically 
significant reduction in self-reported pain levels for children who had treatment with LLLT 
for mucositis. A larger, retrospective case note analysis was then undertaken, comprising 
319 separate LLLT sessions in 39 patients undergoing LLLT treatment from January 2013 
to July 2014. Paediatric patients with symptomatic oro-pharyngeal mucositis were included 
(aged 4-17 years old). Patients were excluded from this analysis if they were not able to 
communicate their pain score due to communication ability or age. The Diobeam 830 laser 
was used for all treatment, with administered dose (J/cm2) varying according to the 
severity of mucositis (WHO scale 1-4). The pain scores (0-10) were recorded prior to and 
immediately post-treatment on a visual/faces analogue scale (Figure 4), along with daily 
neutrophil counts.  Neutrophils are the most common white blood cell and in this group of 
patients the counts vary greatly depending upon their stage of disease and type of 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Under 9 years old 
Over 9 years old 
Figure 4 
 The results are summarised in the Tables 1- 4 below. The most common WHO grade for 
mucositis was Grade 3 (extensive erythema and ulceration and cannot swallow a solid 
diet). A statistically significant change in pain score was noted with the median change of 
pain score being 2 (P-value <0.0005). No statistically significant relationship between 
neutrophil count and pain response was found (P-value = 0.263), or indeed between pain 
response and type of tumour (blood/solid) (P-value = 0.121). 
 
Results 
 
Summary of malignancies of the 39 patients included in the study 
 
 
 
 
 
 
 
 
 
 
WHO Gradings pre-LLLT of the 319 episodes of treatment analysed 
 
 
 
 
 
 
 
 
 
Table 1: Summary of malignancies and WHO Gradings 
 
 
Type of Tumour Number of Patients 
Solid tumour 19 
Blood borne  14 
Inherited blood disorders 5 
Solid and blood borne 1 
 
WHO Grading Number of patients 
0 8 
1 38 
2 79 
3 149 
4 45 
 
 
 
 
Analysis of Pain Scores 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
*One            
patient reported an increase in pain score 
 
Median change of pain score: 2 units 
P-value <0.0005 
For example: 8/10 pain score pre-treatment to 6/10 post-treatment  
 
 
 
Table 2: Pain change results and number of patients with these changes 
 
 
 
X X 
Bar chart showing frequency of changes in pain scores 
* 
  
Neutrophil count of patients at the time of LLLT 
  
 
 
 
 
 
 
 
 
 
 
 
 
No statistical relationship between neutrophil count and pain response was 
found (P-value = 0.263) 
 
Bar chart showing frequency of neutrophil counts 
Table 3: Summary of neutrophil counts at the time of LLLT treatment and comparison with changes 
in pain scores. 
 
 
Pain Response versus Type of tumour 
No statistical relationship between pain response and type of tumour, 
whether blood borne or solid tumour. (P-value = 0.121) 
Table 4: Pain change and tumour results 
 
Parents, staff and patients have embraced LLLT, finding it easy and beneficial, with 
regular requests for treatment and many positive reports. The ward and dental team work 
closely to ensure LLLT is available to those patients who need it and it has been widely 
accepted by the medical team as an effective management tool for mucositis. 
 
Currently in Glasgow, due to resources and staff availability, LLLT is mainly provided when 
patients develop symptomatic mucositis. Our research has shown the ability to reduce 
pain in this patient group and this theoretically should reduce the need for narcotic 
analgesia and allow patients to maintain oral diets. This has been supported with one of 
the pain nurses in Glasgow stating that, ‘The laser provides better pain relief than 
ketamine.’ A patient explained when asked about LLLT ‘my mouth was a 10/10, now it’s a 
0/10.’ Figueiredo et al in 2013 18 conducted a meta-analysis of the prophylactic use of 
LLLT to prevent mucositis and showed a significant positive effect. This research may 
extend our provision of LLLT, utilizing the lowest setting on the laser to provide this.  
 
 
 
 
 
 
 
 
 
Conclusion 
 
As with all new technologies, availability and cost naturally become less of a consideration 
over time. Access to LLLT across medical and dental services will no doubt improve, 
alongside cost effectiveness. A study by Bezinelli et al (2014) has already demonstrated 
that oncology patients with mucositis not treated with LLLT had 30% higher hospitalisation 
costs,19 an important finding for NHS hospitals under mounting financial pressures. 
Provision of LLLT is straightforward, quick and effective for many conditions. LLLT use within 
the specialist dental services continues to expand throughout the UK transforming the care 
we are able to routinely provide. Its use is also expanding in other areas of dental health 
and it will be interesting to see what the future holds for this remarkable technology. 
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Figures 
• Figure 1: Severe grade 4 oral mucositis 
• Figure 2: Diobeam 830 Laser used in Glasgow 
• Figure 3: The LLLT treatment sheet used in Glasgow 
• Figure 4: Pain scales used in Glasgow 
 
Tables 2 and 3 
Graphs taken from statistical report by Johnathan Love B.Sc. ‘Investigating the 
low level light therapy in paediatric patients suffering from chemotherapy 
induced oropharyngeal mucositis.’ 
